We rank companies based on fund manager, research analyst and news sentiment
HOOK stock icon

HOOKIPA Pharma
HOOK

$0.73
3.26%
 

About: HOOKIPA Pharma Inc is a clinical stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. It uses off-the-shelf technologies, VaxWave and TheraT, to elicit directly within patients a response of antigen-specific killer T cells and antibodies.

Employees: 179

0
Funds holding %
of 6,474 funds
0
Analysts bullish %
of 3 analysts
0
News positive %
of 4 articles

Fund manager confidence

Based on 2023 Q4 SEC filings by fund managers ($100M+ AUM)

10% more capital invested

Capital invested by funds: $25.6M [Q3] → $28.2M (+$2.64M) [Q4]

8.21% less ownership

Funds ownership: 50.94% [Q3] → 42.73% (-8.21%) [Q4]

14% less funds holding

Funds holding: 44 [Q3] → 38 (-6) [Q4]

36% less repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 11

50% less funds holding in top 10

Funds holding in top 10: 2 [Q3] → 1 (-1) [Q4]

50% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 12

Research analyst outlook

3 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$5
582%
upside
Avg. target
$5.5
650%
upside
High target
$6.5
787%
upside

3 analyst ratings

positive
100%
neutral
0%
negative
0%
RBC Capital
Brian Abrahams
582%upside
$5
Outperform
Reiterated
25 Mar 2024
HC Wainwright & Co.
Arthur He
787%upside
$6.5
Buy
Reiterated
25 Mar 2024
RBC Capital
Brian Abrahams
582%upside
$5
Outperform
Maintained
30 Jan 2024

Financial journalist opinion

Based on 4 articles about HOOK published over the past 30 days